Chinese Journal of Cancer Research

, Volume 23, Issue 4, pp 317–322

Multicenter clinical study for evaluation of efficacy and safety of transdermal fentanyl matrix patch in treatment of moderate to severe cancer pain in 474 Chinese cancer patients

  • Yu-lin Zhu
  • Guo-hong Song
  • Duan-qi Liu
  • Xi Zhang
  • Kui-feng Liu
  • Ai-hua Zang
  • Ying Cheng
  • Guo-chun Cao
  • Jun Liang
  • Xue-zhen Ma
  • Xin Ding
  • Bin Wang
  • Wei-lian Li
  • Zuo-wei Hu
  • Gang Feng
  • Jiang-jin Huang
  • Xiao Zheng
  • Shun-chang Jiao
  • Rong Wu
  • Jun Ren
Original Article
  • 86 Downloads

Abstract

Objective

Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have been obtained. This study aimed to assess the efficacy and safety of the new system in Chinese patients with moderate to severe cancer pain.

Methods

A total of 474 patients with moderate to severe cancer pain were enrolled in this study and were treated with the new transdermal fentanyl matrix patch (TDF) up to 2 weeks. All the patients were asked to record pain intensity, side effects, quality of life (QOL), adherence and global satisfaction. The initial dose of fentanyl was 25 μg/h titrated with opioid or according to National Comprehensive Cancer Network (NCCN) guidelines. Transdermal fentanyl was changed every three days.

Results

After 2 weeks. The mean pain intensity of the 459 evaluated patients decreased significantly from 5.63±1.26 to 2.03±1.46 (P<0.0001). The total remission rate was 91.29%, of which moderate remission rate 53.16%, obvious remission rate 25.49% and complete remission rate 12.64%. The rate of adverse events was 33.75%, 18.78% of which were moderate and 3.80% were severe. The most frequent adverse events were constipation and nausea. No fatal events were observed. The quality of life was remarkably improved after the treatment (P<0.0001).

Conclusion

The new TDF is effective and safe in treating patients with moderate to severe cancer pain, and can significantly improve the quality of life.

Key words

Transdermal fentanyl matrix patch (TDF) Cancer pain Efficacy Safety Quality of life 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Yu-lin Zhu
    • 1
  • Guo-hong Song
    • 1
  • Duan-qi Liu
    • 2
  • Xi Zhang
    • 3
  • Kui-feng Liu
    • 4
  • Ai-hua Zang
    • 5
  • Ying Cheng
    • 6
  • Guo-chun Cao
    • 7
  • Jun Liang
    • 8
  • Xue-zhen Ma
    • 9
  • Xin Ding
    • 10
  • Bin Wang
    • 11
  • Wei-lian Li
    • 12
  • Zuo-wei Hu
    • 13
  • Gang Feng
    • 14
  • Jiang-jin Huang
    • 15
  • Xiao Zheng
    • 16
  • Shun-chang Jiao
    • 17
  • Rong Wu
    • 18
  • Jun Ren
    • 1
  1. 1.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast OncologyPeking University School of Oncology, Beijing Cancer Hospital & InstituteBeijingChina
  2. 2.The PLA Military General Hospital of BeijingBeijingChina
  3. 3.No. 3 People’s Hospital of ChengduChengduChina
  4. 4.The First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouChina
  5. 5.Hubei Cancer HospitalWuhanChina
  6. 6.Jilin Cancer HospitalChangchunChina
  7. 7.Jiangsu Cancer HospitalNanjingChina
  8. 8.The Affiliated Hospital of Medical College Qingdao UniversityQingdaoChina
  9. 9.Qingdao Cancer HospitalQingdaoChina
  10. 10.Shanghai Huaihai HospitalShanghaiChina
  11. 11.Suzhou Municipal HospitalSuzhouChina
  12. 12.Tianjin People’s HospitalTianjinChina
  13. 13.Wuhan Integrated TCM & Western Medicine HospitalWuhanChina
  14. 14.Pu Ai Hospital of Wuhan CityWuhanChina
  15. 15.Second Affiliated HospitalZhejiang University College of MedicineHangzhouChina
  16. 16.Zhejiang Cancer HospitalHangzhouChina
  17. 17.The General Hospital of the People’s Liberation ArmyBeijingChina
  18. 18.Shengjing Hospital of China Medical UniversityShenyangChina

Personalised recommendations